CinCor Pharma to Present at Upcoming Investor Conferences
CinCor Pharma today announced participation in two upcoming conferences: the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CinCor Pharma today announced participation in two upcoming conferences: the H.C. Wainwright 2022 Global Investment Conference from May 23-26 and the UBS 2022 Global Healthcare Conference from May 23-25. The H.C. Wainwright presentation will be available on-demand starting May 24 at 7 AM EST, while the UBS live presentation is set for May 24 at 7:45 AM EST. CinCor, a clinical-stage biopharmaceutical firm founded in 2018, focuses on innovative treatments for cardio-renal diseases, with its lead asset, baxdrostat (CIN-107), targeting hypertension and primary aldosteronism.
Details
News Market Reaction – CINC
The recorded move for CINC in the trading session of this news was -3.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place on May 23-26 virtually and in Miami, Florida, and at the UBS 2022 Global Healthcare Conference taking place on May 23-25 in New York, New York.
The presentation at the H.C. Wainwright Global Investment Conference will be available to conference registrants on-demand beginning Tuesday, May 24, 2022, at 7:00 AM EST.
The live presentation at the UBS Global Healthcare Conference will be on Tuesday, May 24, 2022, at 7:45 AM EST in New York, New York.
The CinCor management team will participate in one-on-one investor meetings during both events. Investors interested in meeting with CinCor at the conference should contact their respective H.C. Wainwright or UBS representatives.
About CinCor
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat (CIN-107), a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.
About Baxdrostat (CIN-107)
Baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism. Hypertension, which is defined by the American College of Cardiology and the American Heart Association as resting blood pressure above 130/80 mm Hg, is generally acknowledged to be one of the most common preventable risk factors for premature death worldwide. Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke and kidney disease, amongst other diseases. It is estimated that as much as
| Contacts: | Investors: |
| Terry Coelho | Bob Yedid |
| CinCor Pharma, Inc. | LifeSci Advisors |
| EVP, CFO and CBDO | ir@CinCor.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.